HIGH-VOLUME · SEX-BALANCED
ixekizumab Side Effects
ixekizumab (also sold as Taltz) is HIGH-VOLUME in this FAERS book #172 of 524 by FAERS report count. Signature opener: SEX-BALANCED - 61% of sex-coded reports are female (19,946 F / 12,771 M).
Data updated 2026-05-15
- 35,897
- FAERS reports
FAERS voluntary reports, 2016 to 2025. High volume tracks exposure and reporting culture; see methodology for de-dup rules.
ixekizumab reporting skew - 61% of sex-coded reports are female (19,946 F / 12,771 M). Volume band HIGH-VOLUME #172 of 524 by FAERS report count; caseload CASELOAD.
High-report extract for ixekizumab (Taltz): 35,897 FAERS rows (2016-2025). Top named reactions: INJECTION SITE PAIN, PSORIASIS, INJECTION SITE ERYTHEMA. Outcome stamps DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED. FAERS is voluntary signal detection, not incidence.
Counts from the openFDA FAERS extract (2016–2025). Stamps CASELOAD · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
INJECTION SITE PAIN leads 3,851 of 35,897 reports
Who reports · age peak 45-64 (SEX-BALANCED)
Sex coding · SEX-BALANCED
Age peak 45-64 (10,434 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 529 reports (1.5% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 314 |
| COVID-19 | 18 |
| MYOCARDIAL INFARCTION | 18 |
| CARDIAC ARREST | 15 |
| PNEUMONIA | 15 |
| SEPTIC SHOCK | 14 |
| INFECTION | 12 |
| PSORIASIS | 12 |
| MULTIPLE ORGAN DYSFUNCTION SYNDROME | 11 |
| DUODENAL ULCER PERFORATION | 10 |
| HAEMOGLOBIN DECREASED | 8 |
| NEOPLASM MALIGNANT | 8 |
| CARDIAC DISORDER | 7 |
| CEREBROVASCULAR ACCIDENT | 7 |
| DYSPNOEA | 7 |
| HERPES ZOSTER | 7 |
| PULMONARY EMBOLISM | 7 |
| RENAL FAILURE | 7 |
| SEPSIS | 7 |
Reactions in Hospitalization Reports
Hospitalization is lighter here (2,822). Reactions in that subset:
| Reaction | Reports |
|---|---|
| PSORIASIS | 222 |
| CELLULITIS | 156 |
| PNEUMONIA | 152 |
| NAUSEA | 138 |
| ARTHRALGIA | 137 |
| PYREXIA | 132 |
| PAIN | 111 |
| DIARRHOEA | 108 |
| RASH | 100 |
| PRURITUS | 98 |
| FATIGUE | 94 |
| VOMITING | 92 |
| PSORIATIC ARTHROPATHY | 91 |
| COVID-19 | 89 |
| HEADACHE | 89 |
| WEIGHT DECREASED | 85 |
| CARDIAC FAILURE CONGESTIVE | 84 |
| INFECTION | 79 |
How to read ixekizumab FAERS figures (CASELOAD · DEATH-MARKED · HOSP-LIGHT)
FAERS holds 35,897 voluntary reports linked to ixekizumab (Taltz), 2016-2025. Death is listed on 529 (1.5%). Hospitalization appears on 2,822 (7.9%). Top co-reported indication: Psoriasis.
CASELOAD books overweight common drugs and loud reporting cultures; SEX-BALANCED is the page opener, not a per-patient risk.
Read with ixekizumab
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-LIGHT stamps.
ABS(total_reports) peer at 36,174 FAERS cases (Δ 277 heavier vs ixekizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 35,350 FAERS cases (Δ 547 lighter vs ixekizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 35,161 FAERS cases (Δ 736 lighter vs ixekizumab); DEATH-HEAVY · HOSP-MID · FEMALE-LED vs this page's CASELOAD · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(total_reports) peer at 35,138 FAERS cases (Δ 759 lighter vs ixekizumab); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's CASELOAD · DEATH-MARKED · HOSP-LIGHT · SEX-BALANCED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 60.6 pp vs ixekizumab's DEATH-MARKED): CASELOAD · HOSP-MID.
ixekizumab sits in CASELOAD; high report volume tracks exposure and reporting culture more than per-patient risk. Methodology states the de-dup rules.